Literature DB >> 21926185

Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.

A Mekinian1, P Ravaud, P Y Hatron, C Larroche, J Leone, B Gombert, M Hamidou, A Cantagrel, C Marcelli, S Rist, M Breban, D Launay, O Fain, J E Gottenberg, X Mariette.   

Abstract

OBJECTIVE: To evaluate rituximab (RTX) in primary Sjögren's syndrome (pSS) with peripheral nervous system (PNS) involvement.
METHODS: Patients with pSS and PNS involvement who were included in the French AIR registry were analysed.
RESULTS: 17 patients (age 60 years (44-78 years); 14 were female) were analysed. Neurological improvement was noted in 11 patients (65%) at 3 months. Rankin scale decreased from 3 (1-5) to 2 (1-5), 2 (1-5) and 2 (1-6) after 3, 6 and 9 months (p=0.02). European Sjögren's Syndrome Disease Activity Index decreased from 18 (10-44) to 11 (5-20), 11 (5-29) and 12 (5-30) after 3, 6 and 9 months (p<0.05). RTX was effective in neurological involvement in 9/10 patients with vasculitis or cryoglobulinaemia (90%) (group 1) at 3 months and in 2/7 cases (29%) without cryoglobulinaemia and vasculitis (p=0.03). Rankin and European Sjögren's Syndrome Disease Activity Index scales decreased significantly in group 1.
CONCLUSION: RTX seems effective in cryoglobulinaemia or vasculitis-related PNS involvement in pSS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21926185     DOI: 10.1136/annrheumdis-2011-200086

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

Review 1.  Topical and systemic medications for the treatment of primary Sjögren's syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Antoni Sisó-Almirall; Xavier Bosch; Athanasios G Tzioufas
Journal:  Nat Rev Rheumatol       Date:  2012-05-01       Impact factor: 20.543

Review 2.  Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.

Authors:  Pilar Brito-Zerón; Soledad Retamozo; Hoda Gheitasi; Manuel Ramos-Casals
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

Review 3.  Advances in the diagnosis and treatment of Sjogren's syndrome.

Authors:  Xiaoyun Chen; Huaxun Wu; Wei Wei
Journal:  Clin Rheumatol       Date:  2018-05-26       Impact factor: 2.980

Review 4.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 5.  Sjögren syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  CMAJ       Date:  2014-02-24       Impact factor: 8.262

Review 6.  Treatment of primary Sjögren syndrome.

Authors:  Alain Saraux; Jacques-Olivier Pers; Valérie Devauchelle-Pensec
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

Review 7.  Biologic therapy in Sjögren's syndrome.

Authors:  Qin Shao
Journal:  Clin Rheumatol       Date:  2020-10-27       Impact factor: 2.980

8.  Subacute Onset Sensorimotor Axonal Neuropathy with Sicca Syndrome.

Authors:  Ioan-Cristian Lupescu; Mirela Ramona Draghici; Oana Maria Obrisca; Basel Toron; Adriana Octaviana Dulamea
Journal:  Maedica (Bucur)       Date:  2020-12

9.  Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome.

Authors:  Soledad Retamozo; Chiara Baldini; Hendrika Bootsma; Salvatore De Vita; Thomas Dörner; Benjamin A Fisher; Jacques-Eric Gottenberg; Gabriela Hernández-Molina; Agnes Kocher; Belchin Kostov; Aike A Kruize; Thomas Mandl; Wan-Fai Ng; Raphaèle Seror; Yehuda Shoenfeld; Antoni Sisó-Almirall; Athanasios G Tzioufas; Arjan Vissink; Claudio Vitali; Simon J Bowman; Xavier Mariette; Manuel Ramos-Casals; Pilar Brito-Zerón
Journal:  Drugs Aging       Date:  2021-02-23       Impact factor: 3.923

Review 10.  Current and future therapies for primary Sjögren syndrome.

Authors:  Raphaèle Seror; Gaetane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2021-06-29       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.